Bulimia Nervosa Clinical Trial
Official title:
Cognitive Behavioral Therapy for Adolescents With Bulimia Nervosa and Higher Weight (Online Treatment Study)
This study will test the feasibility and acceptability of two treatments for adolescents with higher weight seeking treatment for bulimia nervosa (binge eating and purging, or going to extremes to lose weight).
Status | Recruiting |
Enrollment | 40 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years to 19 Years |
Eligibility | Inclusion Criteria: - Have higher weight (>85th BMI percentile or >85th percentile in past year) - 2 binge/purge episodes per month for the prior 3 months - Be otherwise-healthy youth (i.e., no uncontrolled or serious medical conditions); - Read, comprehend, and write English at a sufficient level to complete study-related materials; - Provide an approval form from a healthcare provider; - Provide a signed and dated written assent (or consent for youth age 18 or 19) prior to study participation; - Provide a signed and dated written consent from one parent prior to study participation; - Be available for participation in the study for 4 months. Exclusion Criteria: - Medical or psychiatric conditions requiring hospitalization or intensive care - anorexia nervosa - developmental or cognitive disorders that would interfere with therapy - pregnancy or breastfeeding - concurrent treatments (medication or psychological) influencing appetite or weight - began hormone therapy in prior 3 months |
Country | Name | City | State |
---|---|---|---|
United States | Yale University (Teen Power - Online) | New Haven | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Yale University | National Eating Disorders Association |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Bulimia nervosa remission assessed by the Eating Disorder Examination Questionnaire (EDE-Q) | Remission from binge eating and purging behaviors will be assessed by EDE-Q. The EDE-Q is a self-report questionnaire with four subscales and a global severity score. the global score ranges from 0-6 with higher scores reflecting greater severity of eating disorder behaviors. | baseline and post-treatment (Month 4) | |
Secondary | Change in Binge eating frequency assessed by the EDE-Q | Number of episodes of binge eating in past month | baseline and post-treatment (Month 4) | |
Secondary | Change in Purging frequency assessed by the EDE-Q | Number of episodes of purging in past month | baseline and post-treatment (Month 4) | |
Secondary | Change in eating disorder psychopathology assessed by the Eating Disorder Examination Questionnaire (EDE-Q) global score. | Eating disorder psychopathology will be assessed using the EDE-Q global score. The EDE-Q is a self-report questionnaire with four subscales and a global severity score. the global score ranges from 0-6 with higher scores reflecting greater severity of eating disorder psychopathology. | baseline and post-treatment (Month 4) | |
Secondary | Change in Depression assessed using Patient Health Questionnaire-9 (PHQ-9) | Depression will be assessed using the PHQ-9. PHQ-9 is a validated questionnaire used to screen for depression with a range of scores from 0-27. Higher scores indicate more severe depressive symptoms. | baseline and post-treatment (Month 4) | |
Secondary | Change in Self-esteem assessed using the Rosenberg Self-Esteem Scale (RSES) | Self-esteem will be assessed using the RSES. The RSES is a self-report measure that consists of 10 statements related to overall feelings of self-worth or self-acceptance. The items are answered on a four-point scale ranging from strongly agree to strongly disagree. The total score ranges from 0 to 30 with higher scores indicating higher self esteem. | baseline and post-treatment (Month 4) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04174703 -
Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing
|
N/A | |
Terminated |
NCT04278755 -
Binge Eating & Birth Control
|
Phase 2 | |
Withdrawn |
NCT02978742 -
Evaluating and Implementing a Smartphone Application Treatment Program for Bulimia Nervosa and Binge Eating Disorder
|
N/A | |
Withdrawn |
NCT00988481 -
Topiramate Augmentation in Bulimia Nervosa Partial Responders
|
Phase 4 | |
Completed |
NCT00184301 -
A Comparison Study of Treatments Given to Patients With Concurrent Eating Disorder and Personality Disorder.
|
N/A | |
Completed |
NCT00522769 -
Cognitive Behavioral Therapy to Treat Bulimia Nervosa in Adolescents
|
Phase 1/Phase 2 | |
Completed |
NCT00304187 -
Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa
|
Phase 2 | |
Recruiting |
NCT04409457 -
Self-Control in Bulimia Nervosa
|
N/A | |
Recruiting |
NCT05509257 -
Naltrexone Neuroimaging in Teens With Eating Disorders
|
Early Phase 1 | |
Recruiting |
NCT05937243 -
Identifying Effective Technological-based Augmentations to Enhance Outcomes From Self-help Cognitive Behavior Therapy for Binge Eating
|
N/A | |
Recruiting |
NCT05862389 -
Study on the Mechanism of Eating Disorder
|
||
Recruiting |
NCT05728021 -
Smartphone-based Aftercare for Inpatients With Bulimia Nervosa
|
N/A | |
Completed |
NCT03781921 -
The Neural Bases of Emotion Regulation in Bulimia Nervosa
|
||
Completed |
NCT02553824 -
FDA Approved Medication to Reduce Binge Eating and/or Purging
|
Phase 1 | |
Terminated |
NCT04041024 -
Decision-making and Risk-taking in Bulimia
|
N/A | |
Completed |
NCT04265131 -
Emotion Regulation in Eating Disorders: How Can Art Therapy Contribute to Treatment Outcome?
|
N/A | |
Recruiting |
NCT06431854 -
Evaluation of a New Treatment Program for Adolescents With Eating Disorders: MINERVA Program
|
N/A | |
Recruiting |
NCT02960152 -
Periodontal Impact of Eating Disorders (the PERIOED Study)
|
N/A | |
Completed |
NCT00916071 -
Association Between Attention Deficit Hyperactivity Disorder and Bulimia Nervosa in Outpatients With Eating Disorders
|
N/A | |
Terminated |
NCT00308776 -
Cholecystokinin for Reducing Binge Eating in People With Bulimia Nervosa
|
N/A |